Aakash Desai, Assistant Professor at UAB O’Neal Comprehensive Cancer Center, posted on LinkedIn:
“Exciting news for extensive-stage small-cell lung cancer (ES-SCLC)!
The FDA has granted breakthrough therapy designation (BTD) to sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients whose disease has progressed after platinum-based chemotherapy.
Key findings from the phase II TROPiCS-03 trial:
- Overall Response Rate (ORR): 41.9%.
- Disease Control Rate: 83.7%.
- Clinical Benefit Rate: 48.8%.
- Median Duration of Response: 4.7 months.
The favorable safety and efficacy data are paving the way for phase III trials. Hopefully, this BTD marks a step forward in improving outcomes for ES-SCLC patients.”